1
|
Aliper AM, Frieden-Korovkina VP, Buzdin A, Roumiantsev SA, Zhavoronkov A. Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancer. Oncotarget 2015; 5:11345-53. [PMID: 25294811 PMCID: PMC4294358 DOI: 10.18632/oncotarget.2489] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2014] [Accepted: 09/15/2014] [Indexed: 12/30/2022] Open
Abstract
In solid cancers, myeloid derived suppressor cells (MDSC) infiltrate (peri)tumoral tissues to induce immune tolerance and hence to establish a microenvironment permissive to tumor growth. Importantly, the mechanisms that facilitate such infiltration or a subsequent immune suppression are not fully understood. Hence, in this study, we aimed to delineate disparate molecular pathways which MDSC utilize in murine models of colon or breast cancer. Using pathways enrichment analysis, we completed interactome maps of multiple signaling pathways in CD11b+/Gr1(high/low) MDSC from spleens and tumor infiltrates of mice with c26GM colon cancer and tumor infiltrates of MDSC in 4T1 breast cancer. In both cancer models, infiltrating MDSC, but not CD11b+ splenic cells, have been found to be enriched in multiple signaling molecules suggestive of their enhanced proliferative and invasive phenotypes. The interactome data has been subsequently used to reconstruct a previously unexplored regulation of MDSC cell cycle by the c-myc transcription factor which was predicted by the analysis. Thus, this study represents a first interactome mapping of distinct multiple molecular pathways whereby MDSC sustain cancer progression.
Collapse
Affiliation(s)
- Alexander M Aliper
- Federal Clinical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia. Insilico Medicine, Inc., Johns Hopkins University, Baltimore, MD, USA
| | | | - Anton Buzdin
- Federal Clinical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia. Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Miklukho-Maklaya, Moscow, Russia. Pathway Pharmaceuticals, Limited, Wan Chai, Hong Kong
| | - Sergey A Roumiantsev
- Federal Clinical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia. Pirogov Russian National Research Medical University, Moscow, Russia. Moscow Institute of Physics and Technology, Dolgoprudny, Moscow, Russian
| | - Alex Zhavoronkov
- Federal Clinical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia. Insilico Medicine, Inc., Johns Hopkins University, Baltimore, MD, USA. Moscow Institute of Physics and Technology, Dolgoprudny, Moscow, Russian. The Biogerontology Research Foundation, BGRF, London, UK
| |
Collapse
|
2
|
Aliper AM, Csoka AB, Buzdin A, Jetka T, Roumiantsev S, Moskalev A, Zhavoronkov A. Signaling pathway activation drift during aging: Hutchinson-Gilford Progeria Syndrome fibroblasts are comparable to normal middle-age and old-age cells. Aging (Albany NY) 2015; 7:26-37. [PMID: 25587796 PMCID: PMC4350323 DOI: 10.18632/aging.100717] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
For the past several decades, research in understanding the molecular basis of human aging has progressed significantly with the analysis of premature aging syndromes. Progerin, an altered form of lamin A, has been identified as the cause of premature aging in Hutchinson-Gilford Progeria Syndrome (HGPS), and may be a contributing causative factor in normal aging. However, the question of whether HGPS actually recapitulates the normal aging process at the cellular and organismal level, or simply mimics the aging phenotype is widely debated. In the present study we analyzed publicly available microarray datasets for fibroblasts undergoing cellular aging in culture, as well as fibroblasts derived from young, middle-age, and old-age individuals, and patients with HGPS. Using GeroScope pathway analysis and drug discovery platform we analyzed the activation states of 65 major cellular signaling pathways. Our analysis reveals that signaling pathway activation states in cells derived from chronologically young patients with HGPS strongly resemble cells taken from normal middle-aged and old individuals. This clearly indicates that HGPS may truly represent accelerated aging, rather than being just a simulacrum. Our data also points to potential pathways that could be targeted to develop drugs and drug combinations for both HGPS and normal aging.
Collapse
Affiliation(s)
- Alexander M Aliper
- Insilico Medicine, Inc., Johns Hopkins University, ETC, B301, MD 21218, USA.,Federal Clinical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
| | - Antonei Benjamin Csoka
- Vision Genomics LLC, Washington DC 20011, USA.,Epigenetics Laboratory, Dept. of Anatomy, Howard University, Washington DC 20059, USA
| | - Anton Buzdin
- Insilico Medicine, Inc., Johns Hopkins University, ETC, B301, MD 21218, USA.,Pathway Pharmaceuticals, Limited, Wan Chai, Hong Kong
| | - Tomasz Jetka
- Institute of Fundamental Technological Research, Polish Academy of Sciences, 02-106 Warsaw, Poland
| | - Sergey Roumiantsev
- Insilico Medicine, Inc., Johns Hopkins University, ETC, B301, MD 21218, USA.,Pirogov Russian National Research Medical University, Moscow 117997, Russia.,Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region 141700, Russia
| | - Alexy Moskalev
- Insilico Medicine, Inc., Johns Hopkins University, ETC, B301, MD 21218, USA.,Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region 141700, Russia.,George Mason University, Fairfax, VA 22030, USA
| | - Alex Zhavoronkov
- Insilico Medicine, Inc., Johns Hopkins University, ETC, B301, MD 21218, USA.,Federal Clinical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.,Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region 141700, Russia.,The Biotechnology Research Foundation, BGRF, London W1J 5NE, UK
| |
Collapse
|
3
|
Zhu Q, Izumchenko E, Aliper AM, Makarev E, Paz K, Buzdin AA, Zhavoronkov AA, Sidransky D. Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients. Hum Genome Var 2015; 2:15009. [PMID: 27081524 PMCID: PMC4785572 DOI: 10.1038/hgv.2015.9] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2014] [Revised: 01/06/2015] [Accepted: 01/11/2015] [Indexed: 12/21/2022] Open
Abstract
Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), was shown to be active in colorectal cancer. Although some patients who harbor K-ras wild-type tumors benefit from cetuximab treatment, 40 to 60% of patients with wild-type K-ras tumors do not respond to cetuximab. Currently, there is no universal marker or method of clinical utility that could guide the treatment of cetuximab in colorectal cancer. Here, we demonstrate a method to predict response to cetuximab in patients with colorectal cancer using OncoFinder pathway activation strength (PAS), based on the transcriptomic data of the tumors. We first evaluated our OncoFinder pathway activation strength model in a set of transcriptomic data obtained from patient-derived xenograft (PDx) models established from colorectal cancer biopsies. Then, the approach and models were validated using a clinical trial data set. PAS could efficiently predict patients’ response to cetuximab, and thus holds promise as a selection criterion for cetuximab treatment in metastatic colorectal cancer.
Collapse
Affiliation(s)
| | - Evgeny Izumchenko
- Department of Otolaryngology-Head & Neck Surgery, Johns Hopkins University School of Medicine , Baltimore, MD, USA
| | - Alexander M Aliper
- InSilico Medicine, Inc., Baltimore, MD, USA; Laboratory of Bioinformatics, D. Rogachyov Federal Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia; Pathway Pharmaceuticals, Wan Chai, Hong Kong, Hong Kong SAR
| | | | - Keren Paz
- Champions Oncology, Inc. , Baltimore, MD, USA
| | - Anton A Buzdin
- Laboratory of Bioinformatics, D. Rogachyov Federal Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia; Pathway Pharmaceuticals, Wan Chai, Hong Kong, Hong Kong SAR; Group for Genomic Regulation of Cell Signaling Systems, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia
| | - Alex A Zhavoronkov
- InSilico Medicine, Inc., Baltimore, MD, USA; Laboratory of Bioinformatics, D. Rogachyov Federal Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia; Pathway Pharmaceuticals, Wan Chai, Hong Kong, Hong Kong SAR
| | - David Sidransky
- Department of Otolaryngology-Head & Neck Surgery, Johns Hopkins University School of Medicine , Baltimore, MD, USA
| |
Collapse
|
4
|
Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, Wang RY, Brisken C, Guerra R, Andreeff M, Mani SA. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 2011; 28:1435-45. [PMID: 20572012 DOI: 10.1002/stem.467] [Citation(s) in RCA: 205] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The epithelial-to-mesenchymal transition (EMT) is an embryonic process that becomes latent in most normal adult tissues. Recently, we have shown that induction of EMT endows breast epithelial cells with stem cell traits. In this report, we have further characterized the EMT-derived cells and shown that these cells are similar to mesenchymal stem cells (MSCs) with the capacity to differentiate into multiple tissue lineages. For this purpose, we induced EMT by ectopic expression of Twist, Snail, or transforming growth factor-beta in immortalized human mammary epithelial cells. We found that the EMT-derived cells and MSCs share many properties including the antigenic profile typical of MSCs, that is, CD44(+), CD24(-), and CD45(-). Conversely, MSCs express EMT-associated genes, such as Twist, Snail, and mesenchyme forkhead 1 (FOXC2). Interestingly, CD140b (platelet-derived growth factor receptor-beta), a marker for naive MSCs, is exclusively expressed in EMT-derived cells and not in their epithelial counterparts. Moreover, functional analyses revealed that EMT-derived cells but not the control cells can differentiate into alizarin red S-positive mature osteoblasts, oil red O-positive adipocytes and alcian blue-positive chondrocytes similar to MSCs. We also observed that EMT-derived cells but not the control cells invade and migrate towards MDA-MB-231 breast cancer cells similar to MSCs. In vivo wound homing assays in nude mice revealed that the EMT-derived cells home to wound sites similar to MSCs. In conclusion, we have demonstrated that the EMT-derived cells are similar to MSCs in gene expression, multilineage differentiation, and ability to migrate towards tumor cells and wound sites.
Collapse
Affiliation(s)
- Venkata Lokesh Battula
- Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation, The University of Texas-M.D. Anderson Cancer Center, Houston, Texas, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Sima C, Hua J, Jung S. Inference of gene regulatory networks using time-series data: a survey. Curr Genomics 2009; 10:416-29. [PMID: 20190956 PMCID: PMC2766792 DOI: 10.2174/138920209789177610] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2008] [Revised: 02/28/2009] [Accepted: 03/02/2009] [Indexed: 11/22/2022] Open
Abstract
The advent of high-throughput technology like microarrays has provided the platform for studying how different cellular components work together, thus created an enormous interest in mathematically modeling biological network, particularly gene regulatory network (GRN). Of particular interest is the modeling and inference on time-series data, which capture a more thorough picture of the system than non-temporal data do. We have given an extensive review of methodologies that have been used on time-series data. In realizing that validation is an impartible part of the inference paradigm, we have also presented a discussion on the principles and challenges in performance evaluation of different methods. This survey gives a panoramic view on these topics, with anticipation that the readers will be inspired to improve and/or expand GRN inference and validation tool repository.
Collapse
Affiliation(s)
- Chao Sima
- Address correspondence to this author at the Computational Biology Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA; Tel: 1(602)343-8485; Fax: 1(602)343-8740; E-mail:
| | | | | |
Collapse
|
6
|
Armañanzas R, Inza I, Santana R, Saeys Y, Flores JL, Lozano JA, Peer YVD, Blanco R, Robles V, Bielza C, Larrañaga P. A review of estimation of distribution algorithms in bioinformatics. BioData Min 2008; 1:6. [PMID: 18822112 PMCID: PMC2576251 DOI: 10.1186/1756-0381-1-6] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2008] [Accepted: 09/11/2008] [Indexed: 11/10/2022] Open
Abstract
Evolutionary search algorithms have become an essential asset in the algorithmic toolbox for solving high-dimensional optimization problems in across a broad range of bioinformatics problems. Genetic algorithms, the most well-known and representative evolutionary search technique, have been the subject of the major part of such applications. Estimation of distribution algorithms (EDAs) offer a novel evolutionary paradigm that constitutes a natural and attractive alternative to genetic algorithms. They make use of a probabilistic model, learnt from the promising solutions, to guide the search process. In this paper, we set out a basic taxonomy of EDA techniques, underlining the nature and complexity of the probabilistic model of each EDA variant. We review a set of innovative works that make use of EDA techniques to solve challenging bioinformatics problems, emphasizing the EDA paradigm's potential for further research in this domain.
Collapse
Affiliation(s)
- Rubén Armañanzas
- Department of Computer Science and Artificial Intelligence, University of the Basque Country, Donostia – San Sebastián, Spain
| | - Iñaki Inza
- Department of Computer Science and Artificial Intelligence, University of the Basque Country, Donostia – San Sebastián, Spain
| | - Roberto Santana
- Department of Computer Science and Artificial Intelligence, University of the Basque Country, Donostia – San Sebastián, Spain
| | - Yvan Saeys
- Department of Plant Systems Biology, Ghent University, Ghent, Belgium
- Department of Molecular Genetics, Ghent University, Ghent, Belgium
| | - Jose Luis Flores
- Department of Computer Science and Artificial Intelligence, University of the Basque Country, Donostia – San Sebastián, Spain
| | - Jose Antonio Lozano
- Department of Computer Science and Artificial Intelligence, University of the Basque Country, Donostia – San Sebastián, Spain
| | - Yves Van de Peer
- Department of Plant Systems Biology, Ghent University, Ghent, Belgium
- Department of Molecular Genetics, Ghent University, Ghent, Belgium
| | - Rosa Blanco
- Department of Statistics and Operations Research, Public University of Navarre, Pamplona, Spain
| | - Víctor Robles
- Departamento de Arquitectura y Tecnología de Sistemas Informáticos, Universidad Politécnica de Madrid, Madrid, Spain
| | - Concha Bielza
- Departamento de Inteligencia Artificial, Universidad Politécnica de Madrid, Madrid, Spain
| | - Pedro Larrañaga
- Departamento de Inteligencia Artificial, Universidad Politécnica de Madrid, Madrid, Spain
| |
Collapse
|